|2.||Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
|3.||Non-Hodgkin Lymphoma (Lymphosarcoma)
|4.||Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
|5.||Burkitt Lymphoma (Burkitt's Lymphoma)
|1.||Gascoyne, Randy D: 53 articles (10/2015 - 01/2002)|
|2.||Coiffier, Bertrand: 33 articles (09/2015 - 01/2002)|
|3.||Staudt, Louis M: 29 articles (11/2015 - 04/2002)|
|4.||Rosenwald, Andreas: 27 articles (02/2015 - 06/2002)|
|5.||Chan, Wing C: 27 articles (02/2015 - 04/2002)|
|6.||Vose, Julie M: 26 articles (02/2015 - 10/2005)|
|7.||Sehn, Laurie H: 25 articles (11/2015 - 08/2005)|
|8.||Connors, Joseph M: 25 articles (11/2015 - 01/2002)|
|9.||Suh, Cheolwon: 25 articles (10/2015 - 07/2008)|
|10.||Weisenburger, Dennis D: 25 articles (02/2015 - 04/2002)|
|1.||rituximab (Mabthera)FDA Link
08/01/2005 - "Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia."
08/01/2015 - "Despite the improvement in overall survival in patients with diffuse large B-cell lymphoma (DLBCL) in the rituximab era, the occurrence of central nervous system (CNS) relapse heralds a very poor prognosis. "
10/01/2012 - "We retrospectively reviewed the medical records of 160 patients with diffuse large B-cell lymphoma (DLBCL) in complete remission (CR) following first-line treatment with rituximab-containing therapy. "
08/01/2012 - "Since the introduction of rituximab (R), the prognosis for diffuse large B-cell lymphoma (DLBCL) has markedly improved. "
09/01/2011 - "When rituximab (R) was added to this regimen, the prognosis of diffuse large B-cell lymphoma (DLBCL) was markedly improved. "
|2.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/01/2002 - "The efficacy of elimination of cyclophosphamide from the treatment program of children and adolescents with advanced stage diffuse large cell lymphoma was inconclusive as to its effect on EFS. "
07/01/2001 - "In conclusion the efficacy of elimination of cyclophosphamide from the treatment program of children and adolescents with advanced stage diffuse large cell lymphoma was inconclusive as to its effect on EFS. "
02/01/1985 - "Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. "
10/01/1978 - "Cell cycle agents and cyclophosphamide in the treatment of diffuse histiocytic lymphoma."
04/01/1984 - "This may be the first report of diffuse histiocytic lymphoma following treatment of Wegener's granulomatosis with cyclophosphamide. "
|3.||Vincristine (Oncovin)FDA LinkGeneric
09/01/1995 - "In this study we describe its effect, alone or after sequential use with vincristine (VCR), on the human diffuse large cell lymphoma cell line WSU-DLCL2. "
02/01/2011 - "We report a 63-year-old man with diffuse large B-cell lymphoma at the right testis who inadvertently received intrathecal vincristine. "
07/15/1994 - "A vincristine (Vcr)-resistant subline of the human histiocytic lymphoma cell line U-937 (U-937-vcr) has been established and characterized with respect to its phenotypic features, including growth rate, surface marker expression and ability to respond to differentiation-inducing agents. "
09/30/1985 - "The case of a patient with Charcot-Marie-Tooth syndrome and diffuse large-cell lymphoma, in whom a severe generalized weakness developed after the intravenous administration of vincristine (2 mg) during combination chemotherapy, is reported. "
11/01/2014 - "In the present article, we report a rare case of vincristine-induced blindness in a patient with diffuse large B cell lymphoma. "
|4.||Doxorubicin (Adriamycin)FDA LinkGeneric
11/08/1981 - "The addition of adriamycin gives hope of long remissions and perhaps cure for histiocytic lymphomas, until now of bad prognosis. "
05/01/2015 - "While anthracycline-based treatment can cure diffuse large B-cell lymphoma, most patients over age 80 do not receive doxorubicin due to toxicity concerns. "
01/01/2014 - "Metadherin interference inhibits proliferation and enhances chemo-sensitivity to doxorubicin in diffuse large B cell lymphoma."
01/01/2013 - "Immunodeficient mice bearing human diffuse large B-cell lymphoma (SUDHL-4) xenotransplants were treated intraperitoneally with increasing doses of the cytotoxic agent doxorubicin. "
06/01/2011 - "Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor."
|5.||Prednisone (Sone)FDA LinkGeneric
07/01/1981 - "Four patients with diffuse histiocytic lymphoma (group 1) received prednisone for 5 days every 3 weeks for five courses, and five patients with Hodgkin's disease (group 2) received prednisone for 14 days every 4 weeks for six courses. "
09/01/1983 - "Subacute polyneuropathy that responded to prednisone was the initial symptom in two patients, one of whom was later found to have histiocytic lymphoma and the other, chronic lymphocytic leukemia. "
04/01/1983 - "The patient was treated with cyclophosphamide and prednisone with a good clinical response, but within two years, histiocytic lymphoma developed. "
07/01/1984 - "A monoclonal diffuse histiocytic lymphoma developed during the course of a serologically documented primary Epstein-Barr virus infection in a 22-year-old cardiac transplant recipient taking cyclosporine and prednisone. "
11/08/2012 - "TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy. "
|6.||Prednisolone (Predate)FDA LinkGeneric
12/01/2012 - "We report a case of diffuse large B-cell lymphoma (DLBCL) treated successfully with clarithromycin (CAM) and prednisolone (PSL). "
12/01/2012 - "Successful treatment of diffuse large B-cell lymphoma with clarithromycin and prednisolone."
04/01/2011 - "We previously described the benefit of the THP-COP regimen comprising cyclophosphamide, THP, vincristine, and prednisolone for elderly patients with diffuse large B-cell lymphoma (DLBCL). "
04/01/2013 - "A 65-year-old woman presented with a rapidly growing mass in her left scapular region 8 years after successful chemotherapy with the cyclophosphamide, hydroxydaunomycin hydrochloride, vincristine, prednisolone regimen for diffuse large B-cell lymphoma. "
01/01/2014 - "The biopsy and immunohistochemistry of this lymph node revealed a CD5 positive diffuse large B-cell lymphoma, but unfortunately the patient succumbed to his illness after receiving the first cycle of Rituximab-Cyclophosphamide-Hydroxydoxorubicin-Oncovin-Prednisolone. "
|7.||Etoposide (VP 16)FDA LinkGeneric
11/01/1992 - "Oral etoposide in the treatment of cutaneous large-cell lymphomas. "
07/01/2015 - "Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma."
02/01/2005 - "[Successful treatment with etoposide by oral administration for recurrence of gastric diffuse large B-cell lymphoma after surgical resection--a case report]."
01/01/1985 - "Etoposide, at a dosage of 100 mg/m2 (156 mg in 250 ml 0.154 M NaCl), was instilled through a thoracostomy tube into the left pleural cavity of a 60-year-old woman with diffuse histiocytic lymphoma and a refractory, recurrent, malignant left pleural effusion. "
01/15/1990 - "Pre-treatment with low, non-toxic concentrations (0.04 microM) of methotrexate (MTX) for 16 hr increased etoposide (VP16)-induced growth inhibition and cytotoxicity in the U937 human histiocytic lymphoma cell line. "
|8.||Methotrexate (Mexate)FDA LinkGeneric
06/01/2007 - "[2-year complete remission after withdrawal of methotrexate in a rectal methotrexate-associated diffuse large B-cell lymphoma]."
03/01/2015 - "This study evaluated the efficacy of central nervous system (CNS) prophylaxis using intrathecal methotrexate (IT-MTX) in patients with diffuse large B-cell lymphoma (DLBCL). "
06/01/2013 - "Posterior reversible encephalopathy after intrathecal methotrexate therapy in diffuse large B-cell lymphoma."
10/01/2012 - "(11)C-methionine PET/CT and MRI of primary central nervous system diffuse large B-cell lymphoma before and after high-dose methotrexate."
06/01/2011 - "Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma."
|9.||lenalidomide (CC 5013)FDA Link
01/01/2014 - "A lenalidomide-based regimen was highly effective in this patient with diffuse large B-cell lymphoma."
01/20/2015 - "Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study."
06/01/2014 - "Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial."
01/20/2015 - "Lenalidomide has significant single-agent activity in relapsed diffuse large B-cell lymphoma (DLBCL). "
01/01/2015 - "Lenalidomide has been shown to produce durable responses in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). "
|10.||Bleomycin (Blenoxane)FDA LinkGeneric
03/15/1983 - "Survival of patients with large cell lymphoma treated with CHOP-BCG was better than that observed with CHOP-bleomycin (P = 0.02) or COP-Bleomycin (P = 0.002). "
03/15/1983 - "CR rate for 65 patients with large cell lymphoma treated with CHOP-BCG was 68% compared to 48% in 61 patients treated with CHOP-bleomycin (P = 0.02) (two-tailed test) or 44% for 45 patients treated with COP-bleomycin (P = 0.02). "
01/01/1982 - "A patient with retroperitoneal diffuse histiocytic lymphoma treated with combination chemotherapy developed breathlessness and fever after receiving 30 units of bleomycin. "
11/01/1990 - "A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. "
02/01/1986 - "[Complete remission obtained by sequential chemotherapy of L-asparaginase and continuous infusion of bleomycin (ABLE protocol) in a case of refractory diffuse large cell lymphoma of a paranasal origin]."
|1.||Drug Therapy (Chemotherapy)
11/01/2015 - "Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis."
09/01/2014 - "Herein, we report the case of a 17-yr-old boy with WAS who received an unrelated HSCT while in complete remission of diffuse large B-cell lymphoma after chemotherapy. "
01/01/2012 - "To examine the efficacy of different radiation doses after achievement of a complete response to chemotherapy in diffuse large B-cell lymphoma (DLBCL). "
07/01/2011 - "The efficacy of high-dose chemotherapy followed by autologous hematopoietic SCT for relapsed diffuse large B-cell lymphoma (DLBCL) has been reported, but an optimal conditioning regimen has not been determined. "
05/01/2008 - "In order to identify genes associated with primary chemotherapy-resistance, gene expression profiles (GEP) in tumour tissue from 37 patients with de novo diffuse large B-cell lymphoma (DLBCL), stage II-IV, either in continuous complete remission (n = 24) or with progressive disease during primary treatment (n = 13), were examined using spotted 55K oligonucleotide arrays. "
|2.||Stem Cell Transplantation
01/01/2008 - "Improved survival has been observed in poor-risk diffuse large B-cell lymphoma (DLBCL) patients treated with high-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) in first complete remission. "
01/01/2008 - "High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission."
09/01/2014 - "90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment."
06/01/2006 - "Forty patients with relapsed diffuse large B cell lymphoma (DLBCL) autografted in partial response (PR) (n = 23) or in refractory relapse (RR) (n = 17) achieved complete remission (CR) after autologous stem cell transplantation (ASCT). "
06/01/2010 - "Patients with diffuse large B-cell lymphoma (DLBCL) who are not cured by initial therapy sometimes experience disease-free survival after autologous stem cell transplantation. "
06/01/2005 - "CHOP followed by radiotherapy is safe and highly effective in localized gastric diffuse large B-cell lymphoma. "
09/01/2006 - "One patient received local radiotherapy to a solitary cutaneous site of large-cell lymphoma that developed after 3 years in remission from the low-grade CBCL; no recurrences of either grade CBCL have yet occurred. "
07/01/2006 - "CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation."
06/01/2005 - "Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach."
11/10/2015 - "Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy?"
|4.||Combination Drug Therapy (Combination Chemotherapy)
10/15/1990 - "Two patients received combination chemotherapy using established treatment protocol for large cell lymphoma, and remain in complete clinical remission and two patients are responding clinically to combination chemotherapy. "
01/01/2003 - "One hundred and seventeen patients with diffuse large B-cell lymphoma achieved complete remission at the Royal Marsden Hospital using first line combination chemotherapy between January 1992 and January 2000. "
02/01/1992 - "It is concluded that noncross resistant alternating combination chemotherapy of CHOP and BEMP is effective for diffuse large cell lymphoma."
10/01/1978 - "In contrast, advanced histiocytic lymphoma, which is rapidly fatal when single-agent therapy is used, is cured in half of patients receiving new combination chemotherapy regimens. "
03/01/2009 - "This study aimed to identify and evaluate molecular targets for the development of a novel combination chemotherapy to treat refractory and recurrent diffuse large B-cell lymphoma (DLBCL). "
04/01/2006 - "Phase II studies have demonstrated that SV is active and well tolerated in relapsed diffuse large B cell lymphoma (DLBCL), including patients who have relapsed following an autologous stem cell transplant. "
10/01/2015 - "This report describes a 61-year-old man who presented after an orthotopic liver transplant with a large periportal soft tissue mass that was shown on biopsy to be a monomorphic, CD20+, diffuse, large B-cell lymphoma, nongerminal center type. "
07/01/2015 - "Recent progress: hematopoietic cell transplant for diffuse large B-cell lymphoma."
02/01/2015 - "Absolute monocyte count is a prognostic indicator in a patient with diffuse large B-cell lymphoma after autologous peripheral blood stem cell transplant."
02/01/2015 - "Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients."